Published in Invest New Drugs on August 04, 2013
Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST). Int J Clin Exp Pathol (2014) 0.84
Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer. Gastric Cancer (2015) 0.78
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines. Invest New Drugs (2015) 0.76
Aqueous immune mediators in malignant uveal melanomas in comparison to benign pigmented intraocular tumors. Graefes Arch Clin Exp Ophthalmol (2016) 0.75
The biology of uveal melanoma. Cancer Metastasis Rev (2017) 0.75
Epithelial-mesenchymal transition in cancer: Role of the IL-8/IL-8R axis. Oncol Lett (2017) 0.75
Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science (2005) 23.44
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
Structure and functional expression of a human interleukin-8 receptor. Science (1991) 4.74
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res (1987) 2.56
Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci (2008) 2.12
CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem (2008) 1.93
Serum vascular endothelial growth factor (VEGF) levels correlate with number and location of micrometastases in a murine model of uveal melanoma. Br J Ophthalmol (2010) 1.53
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol (2002) 1.49
CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer (2009) 1.27
Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med (Berl) (2000) 1.18
Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines--a clue to radioresistance? J Neurooncol (2005) 1.14
Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol (2000) 1.11
Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma. Invest Ophthalmol Vis Sci (2005) 1.08
Uveal melanoma. J Skin Cancer (2011) 0.98
Ocular melanoma: what's new? Curr Opin Oncol (2012) 0.91
Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy - Association of interleukin-8 and VEGF with survival. Cytokine (2009) 0.90
Anti-angiogenic therapy in uveal melanoma. Dev Ophthalmol (2011) 0.81
Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Invest Ophthalmol Vis Sci (2012) 0.81
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Invest New Drugs (2012) 0.77
p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell (2003) 2.65
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer (2005) 2.19
Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol (2013) 2.08
Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol (2008) 1.92
False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J Clin Microbiol (2004) 1.46
Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter. J Clin Invest (2010) 1.30
EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences. Crit Rev Oncol Hematol (2007) 1.21
Cancer of the larynx. Crit Rev Oncol Hematol (2003) 1.19
Cancer of the oropharynx. Crit Rev Oncol Hematol (2002) 1.09
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol (2009) 1.06
JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer (2006) 1.03
Loss of reelin expression in breast cancer is epigenetically controlled and associated with poor prognosis. Am J Pathol (2010) 1.01
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys (2006) 1.00
Epigenetic inactivation of 14-3-3 sigma in oral carcinoma: association with p16(INK4a) silencing and human papillomavirus negativity. Cancer Res (2002) 1.00
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res (2013) 0.96
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol (2005) 0.95
Cost of insurance policies for investigator-initiated cancer clinical trials in Italy. Tumori (2005) 0.92
Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology (2006) 0.90
Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag (2007) 0.89
EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res (2010) 0.86
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit Rev Oncol Hematol (2011) 0.86
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther (2005) 0.84
Cardiac side effects of molecular targeted therapies: towards a better dialogue between oncologists and cardiologists. Crit Rev Oncol Hematol (2011) 0.84
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule. Int J Radiat Oncol Biol Phys (2006) 0.83
Impact of age on acute toxicity induced by bio- or chemo-radiotherapy in patients with head and neck cancer. Oral Oncol (2012) 0.83
MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens. Int J Biol Markers (2015) 0.82
Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. Anticancer Drugs (2013) 0.82
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol (2005) 0.82
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int (2008) 0.82
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. Curr Opin Oncol (2006) 0.81
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. Anticancer Res (2011) 0.81
Expression profiling and long lasting responses to chemotherapy in metastatic gastric cancer. Int J Oncol (2010) 0.80
Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications. Leuk Lymphoma (2012) 0.80
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol (2010) 0.79
Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer (2002) 0.79
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma. Int J Biol Markers (2013) 0.79
Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol (2012) 0.79
Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment. Nucleosides Nucleotides Nucleic Acids (2014) 0.78
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Acta Oncol (2006) 0.78
Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol (2009) 0.78
Combination of docetaxel and vandetanib in docetaxel-sensitive or resistant PC3 cell line. Urol Oncol (2011) 0.78
Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther Drug Monit (2009) 0.78
Overexpression of cortactin in head and neck squamous cell carcinomas can be uncoupled from augmented EGF receptor expression. Acta Oncol (2008) 0.78
Combination of bevacizumab and irradiation on uveal melanoma: an in vitro and in vivo preclinical study. Invest New Drugs (2012) 0.77
Concomitant chemotherapy and external radiotherapy plus brachytherapy for locally advanced esophageal cancer: results of a retrospective multicenter study. Tumori (2006) 0.77
The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines. Invest New Drugs (2015) 0.76
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Oral Oncol (2012) 0.76
The cisplatin-irradiation combination suggests that apoptosis is not a major determinant of clonogenic death. Anticancer Drugs (2007) 0.76
Real-world study of everolimus in advanced progressive neuroendocrine tumors. Oncologist (2015) 0.76
Treatment effect of buparlisib, cetuximab and irradiation in wild-type or PI3KCA-mutated head and neck cancer cell lines. Invest New Drugs (2015) 0.76
Prevention and treatment of oral mucositis in patients with head and neck cancer treated with (chemo) radiation: report of an Italian survey. Support Care Cancer (2014) 0.75
Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine (Baltimore) (2016) 0.75
Carboplatin and weekly paclitaxel in non-small cell lung cancer patients unfit for or pretreated with chemotherapy. Anticancer Res (2005) 0.75
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines. Urol Oncol (2012) 0.75
Management of oropharyngeal mycosis in head and neck cancer occurring during (chemo) radiotherapy: an Italian radio-oncologist survey. Tumori (2015) 0.75
Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study. Anticancer Drugs (2016) 0.75
How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. Expert Rev Mol Diagn (2014) 0.75
Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis. J Clin Oncol (2008) 0.75
DPD testing must remain a recommended option, but not a recommended routine test. Ann Oncol (2017) 0.75
A new approach for the pixel map sensitivity (PMS) evaluation of an electronic portal imaging device (EPID). J Appl Clin Med Phys (2013) 0.75
A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer. Anticancer Drugs (2004) 0.75
A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma. Int J Biol Markers (2014) 0.75